JP2007510670A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007510670A5 JP2007510670A5 JP2006538530A JP2006538530A JP2007510670A5 JP 2007510670 A5 JP2007510670 A5 JP 2007510670A5 JP 2006538530 A JP2006538530 A JP 2006538530A JP 2006538530 A JP2006538530 A JP 2006538530A JP 2007510670 A5 JP2007510670 A5 JP 2007510670A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- disease
- thalidomide
- use according
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 25
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 20
- 229960003433 thalidomide Drugs 0.000 claims 20
- 201000010099 disease Diseases 0.000 claims 19
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 201000011510 cancer Diseases 0.000 claims 15
- 239000004480 active ingredient Substances 0.000 claims 12
- 206010060862 Prostate cancer Diseases 0.000 claims 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 10
- 206010039491 Sarcoma Diseases 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 208000003174 Brain Neoplasms Diseases 0.000 claims 7
- 206010009944 Colon cancer Diseases 0.000 claims 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 6
- 206010016654 Fibrosis Diseases 0.000 claims 6
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 6
- 208000025865 Ulcer Diseases 0.000 claims 6
- 239000003098 androgen Substances 0.000 claims 6
- 230000001684 chronic effect Effects 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 230000004761 fibrosis Effects 0.000 claims 6
- 208000005017 glioblastoma Diseases 0.000 claims 6
- 206010023332 keratitis Diseases 0.000 claims 6
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims 6
- 231100000397 ulcer Toxicity 0.000 claims 6
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 4
- 229940111134 coxibs Drugs 0.000 claims 4
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 4
- 230000007850 degeneration Effects 0.000 claims 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 4
- 229960003957 dexamethasone Drugs 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000001394 metastastic effect Effects 0.000 claims 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims 4
- 230000000750 progressive effect Effects 0.000 claims 4
- 201000000306 sarcoidosis Diseases 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 206010073128 Anaplastic oligodendroglioma Diseases 0.000 claims 3
- 206010003571 Astrocytoma Diseases 0.000 claims 3
- 206010006143 Brain stem glioma Diseases 0.000 claims 3
- 206010016935 Follicular thyroid cancer Diseases 0.000 claims 3
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 3
- 206010018338 Glioma Diseases 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 3
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 3
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 3
- 208000009018 Medullary thyroid cancer Diseases 0.000 claims 3
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 206010029260 Neuroblastoma Diseases 0.000 claims 3
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 201000010133 Oligodendroglioma Diseases 0.000 claims 3
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 206010038019 Rectal adenocarcinoma Diseases 0.000 claims 3
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 3
- 206010002022 amyloidosis Diseases 0.000 claims 3
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims 3
- 230000033115 angiogenesis Effects 0.000 claims 3
- 230000001419 dependent effect Effects 0.000 claims 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 3
- 201000003444 follicular lymphoma Diseases 0.000 claims 3
- 201000002222 hemangioblastoma Diseases 0.000 claims 3
- 208000029824 high grade glioma Diseases 0.000 claims 3
- 201000010260 leiomyoma Diseases 0.000 claims 3
- 206010025135 lupus erythematosus Diseases 0.000 claims 3
- 201000011614 malignant glioma Diseases 0.000 claims 3
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims 3
- 206010027191 meningioma Diseases 0.000 claims 3
- 208000021039 metastatic melanoma Diseases 0.000 claims 3
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims 3
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 3
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 3
- 230000000683 nonmetastatic effect Effects 0.000 claims 3
- 201000002628 peritoneum cancer Diseases 0.000 claims 3
- 208000028591 pheochromocytoma Diseases 0.000 claims 3
- 238000010837 poor prognosis Methods 0.000 claims 3
- 201000001281 rectum adenocarcinoma Diseases 0.000 claims 3
- 201000009295 smoldering myeloma Diseases 0.000 claims 3
- 206010062261 spinal cord neoplasm Diseases 0.000 claims 3
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 3
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 2
- 206010001257 Adenoviral conjunctivitis Diseases 0.000 claims 2
- 206010002064 Anaemia macrocytic Diseases 0.000 claims 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 2
- 206010003645 Atopy Diseases 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 2
- 208000002691 Choroiditis Diseases 0.000 claims 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 206010053717 Fibrous histiocytoma Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 208000009889 Herpes Simplex Diseases 0.000 claims 2
- 208000007514 Herpes zoster Diseases 0.000 claims 2
- 201000002563 Histoplasmosis Diseases 0.000 claims 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims 2
- 206010051151 Hyperviscosity syndrome Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 108010002386 Interleukin-3 Proteins 0.000 claims 2
- 102100039064 Interleukin-3 Human genes 0.000 claims 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims 2
- 208000016604 Lyme disease Diseases 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010059282 Metastases to central nervous system Diseases 0.000 claims 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims 2
- 208000027868 Paget disease Diseases 0.000 claims 2
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims 2
- 208000003971 Posterior uveitis Diseases 0.000 claims 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 2
- 201000002154 Pterygium Diseases 0.000 claims 2
- 208000009527 Refractory anemia Diseases 0.000 claims 2
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims 2
- 206010038848 Retinal detachment Diseases 0.000 claims 2
- 206010038910 Retinitis Diseases 0.000 claims 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 2
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 2
- 206010039705 Scleritis Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 2
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 2
- 201000005485 Toxoplasmosis Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 208000021328 arterial occlusion Diseases 0.000 claims 2
- 239000010425 asbestos Substances 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 208000001119 benign fibrous histiocytoma Diseases 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 229960003405 ciprofloxacin Drugs 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 2
- 229960003901 dacarbazine Drugs 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000021373 epidemic keratoconjunctivitis Diseases 0.000 claims 2
- 230000002538 fungal effect Effects 0.000 claims 2
- 208000007565 gingivitis Diseases 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 230000000148 hypercalcaemia Effects 0.000 claims 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 230000002584 immunomodulator Effects 0.000 claims 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims 2
- 230000001861 immunosuppressant effect Effects 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 229960005280 isotretinoin Drugs 0.000 claims 2
- 230000035984 keratolysis Effects 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 201000006437 macrocytic anemia Diseases 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 208000027202 mammary Paget disease Diseases 0.000 claims 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 2
- 229960001924 melphalan Drugs 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 208000001491 myopia Diseases 0.000 claims 2
- 230000004379 myopia Effects 0.000 claims 2
- 201000003142 neovascular glaucoma Diseases 0.000 claims 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims 2
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 claims 2
- 229960000435 oblimersen Drugs 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 210000003101 oviduct Anatomy 0.000 claims 2
- 229960001476 pentoxifylline Drugs 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 2
- 208000028172 protozoa infectious disease Diseases 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 230000004264 retinal detachment Effects 0.000 claims 2
- 230000001177 retroviral effect Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 229910052895 riebeckite Inorganic materials 0.000 claims 2
- 201000004700 rosacea Diseases 0.000 claims 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 2
- 201000006476 shipyard eye Diseases 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 239000000377 silicon dioxide Substances 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 208000006379 syphilis Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 229960000303 topotecan Drugs 0.000 claims 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 2
- 206010044325 trachoma Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 210000003462 vein Anatomy 0.000 claims 2
- 229960004528 vincristine Drugs 0.000 claims 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 2
- 229960002066 vinorelbine Drugs 0.000 claims 2
- 206010068532 5q minus syndrome Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 244000025254 Cannabis sativa Species 0.000 claims 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims 1
- 208000019878 Eales disease Diseases 0.000 claims 1
- 208000037487 Endotoxemia Diseases 0.000 claims 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 claims 1
- 102100028471 Eosinophil peroxidase Human genes 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 claims 1
- 208000033495 Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality Diseases 0.000 claims 1
- 241001303601 Rosacea Species 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 206010047663 Vitritis Diseases 0.000 claims 1
- 208000005946 Xerostomia Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 238000001815 biotherapy Methods 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 239000007894 caplet Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000003053 chromosome 5q deletion syndrome Diseases 0.000 claims 1
- 230000005796 circulatory shock Effects 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 206010013781 dry mouth Diseases 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 208000018821 hormone-resistant prostate carcinoma Diseases 0.000 claims 1
- 208000013653 hyalitis Diseases 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51740503P | 2003-11-06 | 2003-11-06 | |
| PCT/US2004/037083 WO2005046593A2 (en) | 2003-11-06 | 2004-11-04 | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007510670A JP2007510670A (ja) | 2007-04-26 |
| JP2007510670A5 true JP2007510670A5 (enExample) | 2007-09-13 |
Family
ID=34590157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538530A Withdrawn JP2007510670A (ja) | 2003-11-06 | 2004-11-04 | サリドマイドを用いた、癌、及び他の疾患を治療、及び管理する方法ならびに組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20070208057A1 (enExample) |
| EP (2) | EP1684758A4 (enExample) |
| JP (1) | JP2007510670A (enExample) |
| KR (1) | KR20060124607A (enExample) |
| CN (1) | CN1901911A (enExample) |
| AP (1) | AP2006003637A0 (enExample) |
| AU (1) | AU2004288714A1 (enExample) |
| BR (1) | BRPI0416275A (enExample) |
| CA (1) | CA2545128C (enExample) |
| EA (1) | EA200600921A1 (enExample) |
| IL (1) | IL175427A0 (enExample) |
| OA (1) | OA13284A (enExample) |
| WO (1) | WO2005046593A2 (enExample) |
| ZA (1) | ZA200603718B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| MX2009003038A (es) | 2006-09-26 | 2009-04-15 | Celgene Corp | Derivados de quinazolinona 5-sustituidos como agentes antitumorales. |
| PL2081595T3 (pl) * | 2006-09-26 | 2019-11-29 | Genmab As | Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych |
| ES2397292T3 (es) * | 2007-01-15 | 2013-03-06 | Santen Pharmaceutical Co., Ltd | Nuevo derivado de indol que tiene actividad inhibidora de cinasa I B |
| US20090137631A1 (en) * | 2007-11-22 | 2009-05-28 | National Yang-Ming University | Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression |
| WO2010007972A1 (ja) * | 2008-07-14 | 2010-01-21 | 参天製薬株式会社 | カルバモイル基、ウレイド基及び置換オキシ基を有する新規インドール誘導体 |
| EP2289554A1 (en) | 2009-07-31 | 2011-03-02 | Dafra Pharma N.V. | Compositions comprising thalidomide and artemisinin for the treatment of cancer |
| RU2528380C2 (ru) * | 2009-10-20 | 2014-09-20 | Токио Инститьют Оф Текнолоджи | Способ скрининга с использованием фактора, являющегося мишенью для талидомида |
| US20110280849A1 (en) * | 2010-03-26 | 2011-11-17 | Anthrogenesis Corporation | Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds |
| US20110256236A1 (en) * | 2010-04-16 | 2011-10-20 | Erian Girgis | Enhancement of the Anti-Leukemic Effect of Thalidomide |
| ES2664872T3 (es) * | 2010-06-18 | 2018-04-23 | Taiho Pharmaceutical Co., Ltd | Moduladores PRPK-TPRKB y sus usos |
| JP2013537172A (ja) * | 2010-09-09 | 2013-09-30 | トリフォイリウム エーピーエス | 血管新生阻害剤の気道投与 |
| JP2015500001A (ja) | 2011-12-14 | 2015-01-05 | 大鵬薬品工業株式会社 | 組換えｐｒｐｋ−ｔｐｒｋｂ及びその使用 |
| WO2013123620A1 (zh) * | 2012-02-24 | 2013-08-29 | Sun Yinghao | Cul4A在前列腺癌诊断、治疗及预后中的用途 |
| WO2014180882A2 (en) * | 2013-05-07 | 2014-11-13 | Universitat De Barcelona | Treatment of brain metastasis from cancer |
| US20160223547A1 (en) * | 2013-09-13 | 2016-08-04 | Angels SIERRA JIMÉNLEZ | Marker for predicting metastasis of breast cancer |
| ES2954860T3 (es) * | 2014-10-24 | 2023-11-27 | Launx Biomedical Co Ltd | Uso de azelnidipina en la preparación de una composición medicinal para el tratamiento de cánceres |
| KR20190090390A (ko) * | 2016-11-30 | 2019-08-01 | 인트렉손 코포레이션 | 스테로이드 투여 및 면역요법 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| MX2021012901A (es) * | 2019-04-22 | 2021-11-17 | Starton Therapeutics Inc | Metodo de administracion continua de lenalidomida y otros agentes inmunomoduladores. |
| AU2022206272A1 (en) | 2021-01-08 | 2023-07-27 | Starton Therapeutics, Inc. | Stable solutions of immunomodulatory imide compounds for parenteral use |
| CN114788837B (zh) * | 2022-06-07 | 2023-09-05 | 青岛东海药业有限公司 | 一种组合物及其在制备治疗和/或预防化疗引起的恶心呕吐的药物中的应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| JPS63500636A (ja) * | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| WO1992014455A1 (en) | 1991-02-14 | 1992-09-03 | The Rockefeller University | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5360352A (en) * | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US20010056114A1 (en) * | 2000-11-01 | 2001-12-27 | D'amato Robert | Methods for the inhibition of angiogenesis with 3-amino thalidomide |
| US6228879B1 (en) * | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
| US6114355A (en) * | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
| US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5643915A (en) | 1995-06-06 | 1997-07-01 | Andrulis Pharmaceuticals Corp. | Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies |
| US5731325A (en) * | 1995-06-06 | 1998-03-24 | Andrulis Pharmaceuticals Corp. | Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents |
| HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US5798368A (en) * | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| ATE418536T1 (de) * | 1996-08-12 | 2009-01-15 | Celgene Corp | Neue immunotherapeutische mittel und deren verwendung in der reduzierung von cytokinenspiegel |
| DE69734290T2 (de) * | 1996-11-05 | 2006-07-06 | The Children's Medical Center Corp., Boston | Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid |
| US5874448A (en) * | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
| US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
| CZ299253B6 (cs) * | 1998-03-16 | 2008-05-28 | Celgene Corporation | Isoindolinový derivát, jeho použití pro výrobu léciva a farmaceutická kompozice tento derivát obsahující |
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| US20030013739A1 (en) * | 1998-12-23 | 2003-01-16 | Pharmacia Corporation | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia |
| CZ20013338A3 (cs) * | 1999-03-18 | 2002-03-13 | Celgene Corporation | Substituované 1-oxo-a l,3-dioxoisoindoliny a jejich pouľití ve farmaceutických prostředcích pro sníľení koncentrací zánětlivých cytokinů |
| US7182953B2 (en) * | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
| CA2319872C (en) * | 2000-02-02 | 2012-06-19 | Chun-Ying Huang | Pharmaceutical composition for the treatment of hepatocellular carcinoma |
| NZ521937A (en) * | 2000-03-31 | 2004-08-27 | Celgene Corp | Inhibition of cyclooxygenase-2 activity |
| CA2408710C (en) * | 2000-05-15 | 2010-01-26 | Celgene Corp. | Compositions and methods for the treatment of colorectal cancer |
| EP1676577A1 (en) * | 2000-05-15 | 2006-07-05 | Celgene Corporation | Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide |
| ATE322266T1 (de) * | 2000-05-15 | 2006-04-15 | Celgene Corp | Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten |
| US6458810B1 (en) * | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| US20020128228A1 (en) * | 2000-12-01 | 2002-09-12 | Wen-Jen Hwu | Compositions and methods for the treatment of cancer |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| WO2002068414A2 (en) * | 2001-02-27 | 2002-09-06 | The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| ATE428419T1 (de) * | 2001-08-06 | 2009-05-15 | Childrens Medical Center | Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga |
| US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| NZ555692A (en) * | 2002-07-19 | 2009-02-28 | Abbott Biotech Ltd | Treatment of TNF alpha related disorders |
| US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| CL2004001004A1 (es) * | 2003-05-19 | 2005-03-18 | Upjohn Co | Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple. |
-
2004
- 2004-11-04 CA CA002545128A patent/CA2545128C/en not_active Expired - Fee Related
- 2004-11-04 US US10/576,138 patent/US20070208057A1/en not_active Abandoned
- 2004-11-04 EA EA200600921A patent/EA200600921A1/ru unknown
- 2004-11-04 WO PCT/US2004/037083 patent/WO2005046593A2/en not_active Ceased
- 2004-11-04 ZA ZA200603718A patent/ZA200603718B/en unknown
- 2004-11-04 AP AP2006003637A patent/AP2006003637A0/xx unknown
- 2004-11-04 EP EP04800842A patent/EP1684758A4/en not_active Withdrawn
- 2004-11-04 EP EP09004755A patent/EP2077112A1/en not_active Withdrawn
- 2004-11-04 JP JP2006538530A patent/JP2007510670A/ja not_active Withdrawn
- 2004-11-04 BR BRPI0416275-7A patent/BRPI0416275A/pt not_active IP Right Cessation
- 2004-11-04 CN CNA2004800400013A patent/CN1901911A/zh active Pending
- 2004-11-04 KR KR1020067011015A patent/KR20060124607A/ko not_active Withdrawn
- 2004-11-04 AU AU2004288714A patent/AU2004288714A1/en not_active Abandoned
- 2004-11-04 OA OA1200600149A patent/OA13284A/en unknown
-
2006
- 2006-05-04 IL IL175427A patent/IL175427A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007510670A5 (enExample) | ||
| JP2006508131A5 (enExample) | ||
| CA2486141A1 (en) | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases | |
| RU2348407C2 (ru) | Способы и композиции с использованием иммуномодулирующих соединений для лечения и поддержания состояния при раке и других заболеваниях | |
| CA2545128A1 (en) | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases | |
| AU2013299627B2 (en) | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione | |
| EP1389203B1 (en) | Analogs of thalidomide as angiogenesis inhibitors | |
| CN103495169B (zh) | 用于治疗和控制多发性骨髓瘤的方法及组合物 | |
| JP4754967B2 (ja) | １−オキソ−２−（２，６−ジオキソピペリジン−３−イル）−４−メチルイソインドリンを含む脳腫瘍の治療及び管理のための医薬組成物 | |
| JP2008508298A5 (enExample) | ||
| AU2011336397B2 (en) | Chemokine CXCR4 receptor modulators and uses related thereto | |
| US20220135561A1 (en) | Imidazopyridine derivatives | |
| CN108348505B (zh) | 包含磷酸肌醇3-激酶抑制剂和第二抗增殖剂的组合物 | |
| JP7611855B2 (ja) | ユーイング肉腫治療用キノリン系化合物又はその薬学的に許容される塩 | |
| AU2002306596A1 (en) | Analogs of thalidomide as potential angiogenesis inhibitors | |
| KR20070047807A (ko) | 이소인돌린 화합물 및 그의 사용 방법 | |
| CN115698014B (zh) | 用于治疗医学病症的细胞周期蛋白依赖性激酶抑制化合物 | |
| WO2019136244A1 (en) | Heterocyclic compounds for the treatment of abnormal cellular proliferation | |
| CN112043702A (zh) | 用于联合治疗结直肠癌的喹啉类化合物 | |
| CN101223175A (zh) | 二氮杂苯并[de]蒽-3-酮化合物及抑制PARP的方法 | |
| WO2021220185A1 (en) | Azalactam compounds as hpk1 inhibitors | |
| CN117957000A (zh) | 药物组合物及其用途 | |
| US20240336606A1 (en) | Substituted benzo or pyridopyrimidine amine inhibitor, preparation method therefor, and application thereof | |
| HUE025111T2 (en) | 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors | |
| WO2019222521A1 (en) | Cdk inhibitors for the treatment of neoplastic disorders |